Competing risk of death in patients with low, intermediate and high risk of recurrence after radical surgery for clear cell renal cell carcinoma

Competing risk of death in patients with low, intermediate and high risk of recurrence after radical surgery for clear cell renal cell carcinoma

Abstract Objectives Adjuvant pembrolizumab has improved overall survival after surgery for clear cell renal cell carcinoma (ccRCC) with an intermediate‐high and high risk of recurrence according to the inclusion criteria of Keynote‐564 study, but non‐RCC mortality is common during postoperative foll...

Full description

Saved in:
Bibliographic Details
Main Authors: Anna Brännbäck, Ivan Mustonen, Teemu D. Laajala, Paula Vainio, Magnus Lindskog, Anders Kjellman, Per‐Olof Lundgren, Panu M. Jaakkola, Kalle E. Mattila
Format: Article
Language:English
Published: Wiley 2025-07-01
Series:BJUI Compass
Subjects:
adjuvant therapy
kidney cancer
mortality
nephrectomy
prognostic models
risk factors
Online Access:https://doi.org/10.1002/bco2.70047
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/bco2.70047

Similar Items